Nav: Home

Cancer comorbidities reduce clinical trial participation, new SWOG study shows

January 10, 2019

Cancer patients with other illnesses or conditions, such as hypertension, asthma, or a prior cancer, are less likely to talk with their health care provider about a cancer clinical trial, are less likely to be offered to join a clinical trial, and ultimately less likely to enroll in a trial, according to the results of a new SWOG Cancer Research Network study.

Investigators from SWOG, an international cancer clinical trials network funded by the National Cancer Institute (NCI), part of the National Institutes of Health, also reported a timely secondary finding. New recommendations to expand clinical trial eligibility criteria to allow patients with additional illnesses, called comorbidities, as promoted by the American Society of Clinical Oncologists (ASCO), Friends of Cancer Research (Friends), and the U.S. Food and Drug Administration (FDA), would provide opportunities for up to 6,317 cancer patients each year to be allowed to join a trial - and receive an investigational treatment option that could extend or improve their lives.

The SWOG study is the first to examine the relationship between patient comorbidities and trial participation using real-world, patient-level data. Results appear today in JAMA Oncology, with an accompanying editorial and podcast.

"Cancer clinical trials provide high-quality, guideline-based care for cancer patients," said Joseph Unger, PhD, a health services researcher and biostatistician for SWOG at the Fred Hutchinson Cancer Research Center. "But many patients who might benefit from choosing trial participation for their care have historically been ineligible - something ASCO, Friends, and the FDA are moving to change. Our analysis found that their efforts are on target. Comorbidities have a clear, negative impact on both trial decision-making and participation. Allowing people with manageable comorbidities to join trials would increase treatment opportunities for several thousand patients."

The study results are released in the midst of a national policy debate on where to set the bar for cancer trial participation. How can trial eligibility guidelines be set so that they best balance patient access and patient safety? In spring 2017, FDA officials wrote in the New England Journal of Medicine that current cancer trial criteria may be overly restrictive. In fall 2017, ASCO, Friends, and the FDA published a series of special papers on the same topic, with the goal of arriving at new rules that better serve patients by giving them broader access to trials, and that better serve researchers by helping them recruit patient pools that are more representative of the people who ultimately get the treatments being tested.

In the papers, published in the Journal of Clinical Oncology, the authors recommended modifying trial participation guidelines to allow five distinct groups to join trials, including patients with brain metastases, patients as young as 12 years old, patients with HIV/AIDS, patients with a prior cancer diagnosis, and patients with kidney, liver, or other organ dysfunction. This fall, the NCI rolled out new trial templates based on the ASCO/Friends/FDA recommendations to its National Clinical Trials Network - of which SWOG is a part. The NCTN allows for as many as 17,000 cancer patients to enroll each year on its publicly-funded treatment trials offered at hundreds of cancer centers and community hospitals across the country. The FDA is considering a similar change to eligibility criteria to cover cancer trials run by pharmaceutical companies, biotech firms, and other privately-funded organizations.

Unger conducted his SWOG study to better understand the potential impact of these changes. And he had the database to do it. Unger and a SWOG team had previously worked with a technology company to create a survey study which they embedded within the company's online patient decision-making tool to gauge the impact that demographic and socioeconomic variables, such as age and income, have on cancer trial participation. The tool was available to the public on several cancer-related websites, such as the American Cancer Society site.

In total, 5,499 patients participated in the survey, providing rich, detailed information about their disease, comorbidities, and their treatment decisions, including whether they joined a trial. Unger found that most patients - 66 percent - reported one or more secondary illnesses. Among the 18 comorbidities that were examined, the most commonly reported were hypertension, vision loss, arthritis, asthma, hearing loss, and a previous cancer. Based on the team's statistical analysis, the presence of a comorbidity resulted in a decrease in trial discussions with care providers (15 percent fewer), a decrease in trial offers by a care provider (23 percent fewer) and a decrease in trial participation (24 percent fewer) when compared to those with no comorbidities, even after accounting for differences in age, race, sex, and household income. From their results, the team was able to estimate that if the broader ASCO/Friends/FDA trial eligibility guidelines were in place, up to 6,317 additional patients would be allowed to join trials each year. If every comorbidity restriction were removed, up to 11,992 cancer patients could join a trial.

"If you look at the numbers, they tell you that the ASCO/Friends/FDA guidelines were well focused, as they alone would account for more than half of the potential gains from updating eligibility criteria in trials," Unger said. "This would have the short-term impact of helping patients by giving them access to new treatments and have a long-term impact on the discovery of new treatments, speeding the time it takes to run trials and get new treatments to the public."
This SWOG study was supported by the National Institutes of Health through the National Cancer Institute under grant CA189974, The Hope Foundation for Cancer Research, and the Susan G. Komen Research Foundation under grant SAC160066.

Unger's SWOG team includes Dawn L. Hershman, MD, of NewYork-Presbyterian/Columbia University Irving Medical Center; Mark E. Fleury, PhD, of the American Cancer Society Cancer Action Network, Inc.; and Riha Vaidya, PhD, of Fred Hutch.

SWOG Cancer Research Network is part of the National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program, and is part of the oldest and largest publicly-funded cancer research network in the nation. SWOG has nearly 12,000 members in 46 states and six foreign countries who design and conduct clinical trials to improve the lives of people with cancer. SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 3 million years of human life. Learn more at


Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Don't Fear Math
Why do many of us hate, even fear math? Why are we convinced we're bad at it? This hour, TED speakers explore the myths we tell ourselves and how changing our approach can unlock the beauty of math. Guests include budgeting specialist Phylecia Jones, mathematician and educator Dan Finkel, math teacher Eddie Woo, educator Masha Gershman, and radio personality and eternal math nerd Adam Spencer.
Now Playing: Science for the People

#518 With Genetic Knowledge Comes the Need for Counselling
This week we delve into genetic testing - for yourself and your future children. We speak with Jane Tiller, lawyer and genetic counsellor, about genetic tests that are available to the public, and what to do with the results of these tests. And we talk with Noam Shomron, associate professor at the Sackler School of Medicine at Tel Aviv University, about technological advancements his lab has made in the genetic testing of fetuses.